Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 165

1.

Implications of the diagnostic criteria of idiopathic pulmonary fibrosis in clinical practice: Analysis from the Australian Idiopathic Pulmonary Fibrosis Registry.

Jo HE, Glaspole I, Goh N, Hopkins PMA, Moodley Y, Reynolds PN, Chapman S, Walters EH, Zappala C, Allan H, Macansh S, Grainge C, Keir GJ, Hayen A, Henderson D, Klebe S, Heinze SB, Miller A, Rouse HC, Duhig E, Cooper WA, Mahar AM, Ellis S, McCormack SR, Ng B, Godbolt DB, Corte TJ.

Respirology. 2019 Apr;24(4):361-368. doi: 10.1111/resp.13427. Epub 2018 Oct 17.

2.

A stepwise composite echocardiographic score predicts severe pulmonary hypertension in patients with interstitial lung disease.

Bax S, Bredy C, Kempny A, Dimopoulos K, Devaraj A, Walsh S, Jacob J, Nair A, Kokosi M, Keir G, Kouranos V, George PM, McCabe C, Wilde M, Wells A, Li W, Wort SJ, Price LC.

ERJ Open Res. 2018 May 4;4(2). pii: 00124-2017. doi: 10.1183/23120541.00124-2017. eCollection 2018 Apr. Erratum in: ERJ Open Res. 2018 Jul 31;4(3):.

3.

Stochastic Modeling of Groundwater Extractions over a Data-Sparse Region of Australia.

Keir G, Bulovic N, McIntyre N.

Ground Water. 2019 Jan;57(1):97-109. doi: 10.1111/gwat.12658. Epub 2018 Apr 10. Review.

PMID:
29532910
4.

Diagnosis and management of idiopathic pulmonary fibrosis: Thoracic Society of Australia and New Zealand and Lung Foundation Australia position statements summary.

Jo HE, Prasad JD, Troy LK, Mahar A, Bleasel J, Ellis SJ, Chambers DC, Holland AE, Lake FR, Keir G, Goh NS, Wilsher M, de Boer S, Moodley Y, Grainge C, Whitford HM, Chapman SA, Reynolds PN, Beatson D, Jones LJ, Hopkins P, Allan HM, Glaspole I, Corte TJ.

Med J Aust. 2018 Feb 5;208(2):82-88.

PMID:
29385965
5.

Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry.

Jo HE, Glaspole I, Moodley Y, Chapman S, Ellis S, Goh N, Hopkins P, Keir G, Mahar A, Cooper W, Reynolds P, Haydn Walters E, Zappala C, Grainge C, Allan H, Macansh S, Corte TJ.

BMC Pulm Med. 2018 Jan 25;18(1):19. doi: 10.1186/s12890-018-0575-y.

6.

Pulmonary hypertension in interstitial lung disease: Limitations of echocardiography compared to cardiac catheterization.

Keir GJ, Wort SJ, Kokosi M, George PM, Walsh SLF, Jacob J, Price L, Bax S, Renzoni EA, Maher TM, MacDonald P, Hansell DM, Wells AU.

Respirology. 2018 Jul;23(7):687-694. doi: 10.1111/resp.13250. Epub 2018 Jan 12.

7.

Pulmonary schistosomiasis mimicking IgG4-related lung disease.

Baird T, Cooper CL, Wong R, Runnegar N, Keir G.

Respirol Case Rep. 2017 Oct 16;6(1):e00276. doi: 10.1002/rcr2.276. eCollection 2018 Jan.

8.

Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia.

Jo HE, Troy LK, Keir G, Chambers DC, Holland A, Goh N, Wilsher M, de Boer S, Moodley Y, Grainge C, Whitford H, Chapman S, Reynolds PN, Glaspole I, Beatson D, Jones L, Hopkins P, Corte TJ.

Respirology. 2017 Oct;22(7):1436-1458. doi: 10.1111/resp.13146. Epub 2017 Aug 27. Erratum in: Respirology. 2018 Jan;23 (1):116.

PMID:
28845557
9.

Determinants and outcomes of prolonged anxiety and depression in idiopathic pulmonary fibrosis.

Glaspole IN, Watson AL, Allan H, Chapman S, Cooper WA, Corte TJ, Ellis S, Grainge C, Goh N, Hopkins P, Keir G, Macansh S, Mahar A, Moodley Y, Reynolds PN, Ryerson CJ, Walters EH, Zappala CJ, Holland AE.

Eur Respir J. 2017 Aug 17;50(2). pii: 1700168. doi: 10.1183/13993003.00168-2017. Print 2017 Aug. No abstract available.

10.

Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial.

Saunders P, Tsipouri V, Keir GJ, Ashby D, Flather MD, Parfrey H, Babalis D, Renzoni EA, Denton CP, Wells AU, Maher TM.

Trials. 2017 Jun 15;18(1):275. doi: 10.1186/s13063-017-2016-2.

11.

Role of Autoantibodies in the Diagnosis of Connective-Tissue Disease ILD (CTD-ILD) and Interstitial Pneumonia with Autoimmune Features (IPAF).

Jee AS, Adelstein S, Bleasel J, Keir GJ, Nguyen M, Sahhar J, Youssef P, Corte TJ.

J Clin Med. 2017 May 4;6(5). pii: E51. doi: 10.3390/jcm6050051. Review.

12.

Liposomal bupivacaine versus bupivacaine/epinephrine after video-assisted thoracoscopic wedge resection†.

Parascandola SA, Ibañez J, Keir G, Anderson J, Plankey M, Flynn D, Cody C, De Marchi L, Margolis M, Blair Marshall M.

Interact Cardiovasc Thorac Surg. 2017 Jun 1;24(6):925-930. doi: 10.1093/icvts/ivx044.

PMID:
28329326
13.

What's new in neuromyelitis optica? A short review for the clinical neurologist.

Whittam D, Wilson M, Hamid S, Keir G, Bhojak M, Jacob A.

J Neurol. 2017 Nov;264(11):2330-2344. doi: 10.1007/s00415-017-8445-8. Epub 2017 Mar 13. Review.

PMID:
28289845
14.

Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry.

Jo HE, Glaspole I, Grainge C, Goh N, Hopkins PM, Moodley Y, Reynolds PN, Chapman S, Walters EH, Zappala C, Allan H, Keir GJ, Hayen A, Cooper WA, Mahar AM, Ellis S, Macansh S, Corte TJ.

Eur Respir J. 2017 Feb 23;49(2). pii: 1601592. doi: 10.1183/13993003.01592-2016. Print 2017 Feb. Erratum in: Eur Respir J. 2017 Mar 29;49(3):.

15.

Management Strategy for Patients With Chronic Subclavian Vein Thrombosis.

Keir G, Marshall MB.

Ann Thorac Surg. 2017 Feb;103(2):672-675. doi: 10.1016/j.athoracsur.2016.09.051. Epub 2016 Dec 23. Review.

PMID:
28024649
16.

A call for uniformity in implementing the IPAF (interstitial pneumonia with autoimmune features) criteria.

Jee AS, Bleasel JF, Adelstein S, Keir GJ, Corte TJ.

Eur Respir J. 2016 Dec;48(6):1811-1813. doi: 10.1183/13993003.01259-2016. No abstract available.

17.

Prophylactic cranial irradiation in small cell lung cancer: A single institution experience.

Nicholls L, Keir GJ, Murphy MA, Mai T, Lehman M.

Asia Pac J Clin Oncol. 2016 Dec;12(4):415-420. doi: 10.1111/ajco.12564. Epub 2016 Jul 25.

PMID:
27453519
18.

The Interleukin-1 Balance During Encephalitis Is Associated With Clinical Severity, Blood-Brain Barrier Permeability, Neuroimaging Changes, and Disease Outcome.

Michael BD, Griffiths MJ, Granerod J, Brown D, Keir G, Wnęk M, Cox DJ, Vidyasagar R, Borrow R, Parkes LM, Solomon T.

J Infect Dis. 2016 May 15;213(10):1651-60. doi: 10.1093/infdis/jiv771. Epub 2015 Dec 27. Erratum in: J Infect Dis. 2017 Jun 1;215(11):1774.

19.

Pulmonary vasospasm in systemic sclerosis: noninvasive techniques for detection.

Keir GJ, Nair A, Giannarou S, Yang GZ, Oldershaw P, Wort SJ, MacDonald P, Hansell DM, Wells AU.

Pulm Circ. 2015 Sep;5(3):498-505. doi: 10.1086/682221.

20.

Growth associated protein (GAP-43): cloning and the development of a sensitive ELISA for neurological disorders.

Gnanapavan S, Yousaf N, Heywood W, Grant D, Mills K, Chernajovsky Y, Keir G, Giovannoni G.

J Neuroimmunol. 2014 Nov 15;276(1-2):18-23. doi: 10.1016/j.jneuroim.2014.07.008. Epub 2014 Jul 23.

PMID:
25175067
21.

Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders.

Gnanapavan S, Hegen H, Khalil M, Hemmer B, Franciotta D, Hughes S, Hintzen R, Jeromin A, Havrdova E, Tumani H, Bertolotto A, Comabella M, Frederiksen J, Álvarez-Cermeño JC, Villar L, Galimberti D, Myhr KM, Dujmovic I, Fazekas F, Ionete C, Menge T, Kuhle J, Keir G, Deisenhammer F, Teunissen C, Giovannoni G.

Neurology. 2014 Sep 23;83(13):1210-6. doi: 10.1212/WNL.0000000000000809. Epub 2014 Aug 22.

PMID:
25150289
22.

Treatment of sarcoidosis-associated pulmonary hypertension: A single centre retrospective experience using targeted therapies.

Keir GJ, Walsh SL, Gatzoulis MA, Marino PS, Dimopoulos K, Alonso R, Raposeiras-Roubin S, Renzoni EA, Maher TM, Wells AU, Wort SJ.

Sarcoidosis Vasc Diffuse Lung Dis. 2014 Jul 8;31(2):82-90.

PMID:
25078636
23.

Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia.

Corte TJ, Keir GJ, Dimopoulos K, Howard L, Corris PA, Parfitt L, Foley C, Yanez-Lopez M, Babalis D, Marino P, Maher TM, Renzoni EA, Spencer L, Elliot CA, Birring SS, O'Reilly K, Gatzoulis MA, Wells AU, Wort SJ; BPHIT Study Group.

Am J Respir Crit Care Med. 2014 Jul 15;190(2):208-17. doi: 10.1164/rccm.201403-0446OC.

24.

CANOMAD responding to weekly treatment with intravenous immunoglobulin (IVIg).

Krenn M, Keir G, Wieshmann UC.

BMJ Case Rep. 2014 Apr 10;2014. pii: bcr2013202545. doi: 10.1136/bcr-2013-202545.

25.

An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study.

Walsh SL, Wells AU, Sverzellati N, Keir GJ, Calandriello L, Antoniou KM, Copley SJ, Devaraj A, Maher TM, Renzoni E, Nicholson AG, Hansell DM.

Lancet Respir Med. 2014 Feb;2(2):123-30. doi: 10.1016/S2213-2600(13)70276-5. Epub 2014 Jan 15.

26.

Rituximab in severe, treatment-refractory interstitial lung disease.

Keir GJ, Maher TM, Ming D, Abdullah R, de Lauretis A, Wickremasinghe M, Nicholson AG, Hansell DM, Wells AU, Renzoni EA.

Respirology. 2014 Apr;19(3):353-9. doi: 10.1111/resp.12214. Epub 2013 Nov 29.

27.

Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants.

Walsh SL, Sverzellati N, Devaraj A, Keir GJ, Wells AU, Hansell DM.

Thorax. 2014 Mar;69(3):216-22. doi: 10.1136/thoraxjnl-2013-203843. Epub 2013 Oct 14.

PMID:
24127020
28.

Cyclical caspofungin for chronic pulmonary aspergillosis in sarcoidosis.

Keir GJ, Garfield B, Hansell DM, Loebinger MR, Wilson R, Renzoni EA, Wells AU, Maher TM.

Thorax. 2014 Mar;69(3):287-8. doi: 10.1136/thoraxjnl-2013-203988. Epub 2013 Sep 12.

PMID:
24029745
29.

The minimal important difference of the King's Brief Interstitial Lung Disease Questionnaire (K-BILD) and forced vital capacity in interstitial lung disease.

Patel AS, Siegert RJ, Keir GJ, Bajwah S, Barker RD, Maher TM, Renzoni EA, Wells AU, Higginson IJ, Birring SS.

Respir Med. 2013 Sep;107(9):1438-43. doi: 10.1016/j.rmed.2013.06.009. Epub 2013 Jul 16.

30.

Novel use of rituximab in hypersensitivity pneumonitis refractory to conventional treatment.

Lota HK, Keir GJ, Hansell DM, Nicholson AG, Maher TM, Wells AU, Renzoni EA.

Thorax. 2013 Aug;68(8):780-1. doi: 10.1136/thoraxjnl-2013-203265. Epub 2013 Mar 20. No abstract available.

PMID:
23515438
31.

Progression in multiple sclerosis is associated with low endogenous NCAM.

Gnanapavan S, Ho P, Heywood W, Jackson S, Grant D, Rantell K, Keir G, Mills K, Steinman L, Giovannoni G.

J Neurochem. 2013 Jun;125(5):766-73. doi: 10.1111/jnc.12236. Epub 2013 Apr 19.

32.

Elderly individuals with FTLD.

Baborie A, Griffiths TD, Jaros E, Momeni P, McKeith IG, Burn DJ, Keir G, Larner AJ, Mann DM, Perry R.

JAMA Neurol. 2013 Mar 1;70(3):412-3. doi: 10.1001/jamaneurol.2013.1649. No abstract available.

PMID:
23478838
33.

Association of cerebral microbleeds in acute ischemic stroke with high serum levels of vascular endothelial growth factor.

Dassan P, Brown MM, Gregoire SM, Keir G, Werring DJ.

Arch Neurol. 2012 Sep;69(9):1186-9. doi: 10.1001/archneurol.2012.459.

PMID:
22635523
34.

Frontotemporal dementia in elderly individuals.

Baborie A, Griffiths TD, Jaros E, Momeni P, McKeith IG, Burn DJ, Keir G, Larner AJ, Mann DM, Perry R.

Arch Neurol. 2012 Aug;69(8):1052-60. Review.

PMID:
22529248
35.

Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy.

Keir GJ, Maher TM, Hansell DM, Denton CP, Ong VH, Singh S, Wells AU, Renzoni EA.

Eur Respir J. 2012 Sep;40(3):641-8. doi: 10.1183/09031936.00163911. Epub 2012 Jan 26.

36.

Value of measuring serum vascular endothelial growth factor levels in diagnosing acute ischemic stroke.

Dassan P, Keir G, Jäger HR, Brown MM.

Int J Stroke. 2012 Aug;7(6):454-9. doi: 10.1111/j.1747-4949.2011.00677.x. Epub 2011 Nov 22.

PMID:
22103773
37.

Diagnostic strategy used to establish etiologies of encephalitis in a prospective cohort of patients in England.

Ambrose HE, Granerod J, Clewley JP, Davies NW, Keir G, Cunningham R, Zuckerman M, Mutton KJ, Ward KN, Ijaz S, Crowcroft NS, Brown DW; UK Aetiology of Encephalitis Study Group.

J Clin Microbiol. 2011 Oct;49(10):3576-83. doi: 10.1128/JCM.00862-11. Epub 2011 Aug 24.

38.

Improving the detection of pulmonary hypertension in systemic sclerosis using pulmonary function tests.

Schreiber BE, Valerio CJ, Keir GJ, Handler C, Wells AU, Denton CP, Coghlan JG.

Arthritis Rheum. 2011 Nov;63(11):3531-9. doi: 10.1002/art.30535.

39.

Cognitive, biochemical, and imaging profile of patients suffering from idiopathic normal pressure hydrocephalus.

Tarnaris A, Toma AK, Pullen E, Chapman MD, Petzold A, Cipolotti L, Kitchen ND, Keir G, Lemieux L, Watkins LD.

Alzheimers Dement. 2011 Sep;7(5):501-8. doi: 10.1016/j.jalz.2011.01.003. Epub 2011 Jul 14.

PMID:
21757406
40.

Use of cerebrospinal fluid amyloid-β and total tau protein to predict favorable surgical outcomes in patients with idiopathic normal pressure hydrocephalus.

Tarnaris A, Toma AK, Chapman MD, Keir G, Kitchen ND, Watkins LD.

J Neurosurg. 2011 Jul;115(1):145-50. doi: 10.3171/2011.2.JNS101316. Epub 2011 Mar 25.

PMID:
21438653
41.

Rostrocaudal dynamics of CSF biomarkers.

Tarnaris A, Toma AK, Chapman MD, Petzold A, Keir G, Kitchen ND, Watkins LD.

Neurochem Res. 2011 Mar;36(3):528-32. doi: 10.1007/s11064-010-0374-1. Epub 2010 Dec 30. Erratum in: Neurochem Res. 2012 Jan;37(1):232.

PMID:
21191652
42.

Assessing pulmonary disease and response to therapy: which test?

Keir G, Wells AU.

Semin Respir Crit Care Med. 2010 Aug;31(4):409-18. doi: 10.1055/s-0030-1262209. Epub 2010 Jul 27. Review.

PMID:
20665391
43.

Neural cell adhesion molecule--description of a CSF ELISA method and evidence of reduced levels in selected neurological disorders.

Gnanapavan S, Grant D, Illes-Toth E, Lakdawala N, Keir G, Giovannoni G.

J Neuroimmunol. 2010 Aug 25;225(1-2):118-22. doi: 10.1016/j.jneuroim.2010.04.020. Epub 2010 Jun 1.

PMID:
20605643
44.

The longitudinal profile of CSF markers during external lumbar drainage.

Tarnaris A, Toma AK, Chapman MD, Petzold A, Kitchen ND, Keir G, Watkins LD.

J Neurol Neurosurg Psychiatry. 2009 Oct;80(10):1130-3. doi: 10.1136/jnnp.2008.171686. Epub 2009 Jun 16.

PMID:
19535354
45.

CSF protein biomarkers for proximal axonal damage improve prognostic accuracy in the acute phase of Guillain-Barré syndrome.

Petzold A, Brettschneider J, Jin K, Keir G, Murray NM, Hirsch NP, Itoyama Y, Reilly MM, Takeda A, Tumani H.

Muscle Nerve. 2009 Jul;40(1):42-9. doi: 10.1002/mus.21239.

PMID:
19533642
46.

Improving the recovery of S100B protein in cerebral microdialysis: implications for multimodal monitoring in neurocritical care.

Afinowi R, Tisdall M, Keir G, Smith M, Kitchen N, Petzold A.

J Neurosci Methods. 2009 Jun 30;181(1):95-9. doi: 10.1016/j.jneumeth.2009.02.021. Epub 2009 Mar 14.

PMID:
19467712
47.

Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component.

Kolstoe SE, Ridha BH, Bellotti V, Wang N, Robinson CV, Crutch SJ, Keir G, Kukkastenvehmas R, Gallimore JR, Hutchinson WL, Hawkins PN, Wood SP, Rossor MN, Pepys MB.

Proc Natl Acad Sci U S A. 2009 May 5;106(18):7619-23. doi: 10.1073/pnas.0902640106. Epub 2009 Apr 16.

48.

Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients.

Amorini AM, Petzold A, Tavazzi B, Eikelenboom J, Keir G, Belli A, Giovannoni G, Di Pietro V, Polman C, D'Urso S, Vagnozzi R, Uitdehaag B, Lazzarino G.

Clin Biochem. 2009 Jul;42(10-11):1001-6. doi: 10.1016/j.clinbiochem.2009.03.020. Epub 2009 Mar 31.

PMID:
19341721
49.

Criteria for a clinically informative serum biomarker in acute ischaemic stroke: a review of S100B.

Dassan P, Keir G, Brown MM.

Cerebrovasc Dis. 2009;27(3):295-302. doi: 10.1159/000199468. Epub 2009 Feb 6. Review.

50.

Longitudinal one-year study of levels and stoichiometry of neurofilament heavy and light chain concentrations in CSF in patients with multiple system atrophy.

Petzold A, Thompson EJ, Keir G, Quinn N, Holmberg B, Dizdar N, Wenning GK, Rascol O, Tolosa E, Rosengren L.

J Neurol Sci. 2009 Apr 15;279(1-2):76-9. doi: 10.1016/j.jns.2008.12.037. Epub 2009 Feb 4.

PMID:
19195665

Supplemental Content

Support Center